Ensuring Success with Clinical Development Planning
This white paper outlines key elements of a CDP, including Treatment population, Demonstration of efficacy, Demonstration of safety, Clinical supplies, and Timing of activities.
This white paper outlines key elements of a CDP, including Treatment population, Demonstration of efficacy, Demonstration of safety, Clinical supplies, and Timing of activities.
This white paper outlines key elements of a CDP, including Treatment population, Demonstration of efficacy, Demonstration of safety, Clinical supplies, and Timing of activities.
Learn the essentials of IRB reporting, including why it matters, what’s required, what’s not, and tips to avoid common reporting challenges.
This eBook outlines several challenges you may face as you conduct research, and how a clinical trial management system (CTMS) can address them.
Learn what events need to be reported to the IRB after study approval and explore scenarios to help evaluate potentially reportable events.
Expert assistance from Advarra’s regulatory consulting team enabled iSpecimen to implement GDPR with no service interruption to their Eurozone customers.
Learn proactive strategies to overcome site-sponsor challenges and streamline processes for more successful clinical trial partnerships.
Learn how Duke University streamlined clinical operations with Advarra eReg, improving site-centric workflows and reducing administrative burdens.
About the Advarra In Conversations With… The future of healthcare innovation hinges on research and clinical trials. Advarra sits down
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Transcript Institutions, universities, academic medical centers, hospitals, and healthcare systems all play a critical role in clinical research. In the
Adopting a site-centric mindset benefits sponsors and CROs by addressing site challenges, leading to faster startups, better recruitment, fewer deviations, and a stronger research industry.